Rhumatologie, la multitude des options - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue Médecine/Sciences Année : 2019

Rhumatologie, la multitude des options


The number of therapeutic antibodies available in rheumatology increases every year, mainly indicated in chronic inflammatory rheumatisms and other immune-mediated inflammatory diseases. The choice between all these monoclonal antibodies depends on their specificities, patients and diseases characteristics. Until now, there is no reliable biomarker, predictive of response for specialized medicine purpose. Today, therapeutic drug monitoring and anti-drug antibodies testing can help to better adapt the dose of the drug and to help in the decision to switch to another biological drug according to the activity of the inflammatory disease.
Fichier principal
Vignette du fichier
msc190087.pdf (720.48 Ko) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-02519947 , version 1 (08-06-2021)




Jacques Morel, Denis Mulleman. Rhumatologie, la multitude des options. Médecine/Sciences, 2019, 35 (12), pp.1029-1033. ⟨10.1051/medsci/2019204⟩. ⟨hal-02519947⟩
49 Consultations
60 Téléchargements



Gmail Mastodon Facebook X LinkedIn More